Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01098266 · ClinicalTrials.gov registry record · Phase 3
NGR015: Study in Second Line for Patient With Advanced Malignant Pleural Mesothelioma Pretreated With Pemetrexed
A Phase 3 study of Malignant Pleural Mesothelioma, sponsored by AGC Biologics S.p.A..
- Completed
- Registry status
- Phase 3
- Development phase
- 400
- Enrollment target
- 20
- Study locations
NCT01098266 is a Phase 3 study of Malignant Pleural Mesothelioma that has completed, run by AGC Biologics S.p.A.. The registered enrollment target is 400 participants, above the 23-participant average among 6 other Malignant Pleural Mesothelioma trials with a reported enrollment target (1639% higher). The trial reports 20 study locations across 13 states.
The verdict
NCT01098266, a Phase 3 study of Malignant Pleural Mesothelioma, has completed, sponsored by AGC Biologics S.p.A..
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 400 participants
- Enrollment target
- 20
- Study locations
Study Summary
The main objective of the trial is to document the efficacy of NGR-hTNF administered at low dose weekly in advanced Malignant Pleural Mesothelioma patients previously treated with a pemetrexed-based chemotherapy regimen.
Conditions Studied
Interventions
- DRUG NGR-hTNF plus Best Investigator's Choice (BIC)
- DRUG Placebo plus Best Investigator's Choice (BIC)
Study Locations (20)
Other
- Institut Jules Bordet - Brussels
- Cliniques Universitarie St. Luc - Brussels
- Universitair Ziekenhuis - Ghent
- National Cancer Institute - Cairo
- Hôpitaux de Marseille Hôpital Nord - Marseille
- St James's Hospital - Dublin
- Azienda Ospedaliera SS. Antonio e Biagio e Cesare Arrigo di Alessandria - Alessandria
California
- Wilshire Oncology Medical Group - Corona
- City of Hope-Comprehensive Cancer Cente - Duarte
Florida
- H. Lee Moffitt ancer Center and Research Institute - Tampa
Maryland
- Johns Hopkins - Baltimore
New York
- Columbia University - New York
Pennsylvania
- University of Pennsylvania - Philadelphia
Texas
- UTsouthwestern medical center - Dallas
Antwerp
- Antwerp University Hospital - Edegem
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 400 participants |
| Start Date | 2010-04-12 |
| Est. Completion | 2017-12 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01098266
The ClinicalTrials.gov registry entry for NCT01098266 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 400 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 23-participant average among 6 other Malignant Pleural Mesothelioma trials with a reported enrollment target (1639% higher). The listed sponsor is AGC Biologics S.p.A., which has 2 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Malignant Pleural Mesothelioma appearing as the primary indexed condition, and to 2 interventions - of which NGR-hTNF plus Best Investigator's Choice (BIC) is the first listed.
NCT01098266 reports 20 study locations spanning 13 distinct geographic areas - top geographies include Other, California, Florida.
Frequently Asked Questions
What is clinical trial NCT01098266 about?
NCT01098266 is a clinical study titled "NGR015: Study in Second Line for Patient With Advanced Malignant Pleural Mesothelioma Pretreated With Pemetrexed". The main objective of the trial is to document the efficacy of NGR-hTNF administered at low dose weekly in advanced Malignant Pleural Mesothelioma patients previously treated with a pemetrexed-based chemotherapy regimen.
What is the current status of trial NCT01098266?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 400 participants. The study started on 2010-04-12. Estimated completion is 2017-12.
What conditions does trial NCT01098266 study?
This clinical trial studies the following conditions: Malignant Pleural Mesothelioma.
What interventions are being tested in trial NCT01098266?
The interventions under investigation include: NGR-hTNF plus Best Investigator's Choice (BIC) (DRUG), Placebo plus Best Investigator's Choice (BIC) (DRUG).
Who is sponsoring clinical trial NCT01098266?
This trial is sponsored by AGC Biologics S.p.A., which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01098266 being conducted?
This trial has 20 study locations across California, Florida, Maryland, New York, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Malignant Pleural Mesothelioma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Efficacy & Safety of rAd-IFN Administered With Celecoxib & Gemcitabine in Patients With Malignant Pleural Mesothelioma
ACTIVE NOT RECRUITING · Phase 3
-
Using E-Nose Technology to Measure Response to Treatment in People With Malignant Pleural Mesothelioma
RECRUITING · NA
-
A Study of Pembrolizumab and Radiation Therapy in People With Mesothelioma
ACTIVE NOT RECRUITING · Phase 1
-
A Study of Nivolumab and Chemotherapy Followed by Surgery for Mesothelioma
ACTIVE NOT RECRUITING · Phase 1
-
Autologous Redirected RNA Meso-CIR T Cells
COMPLETED · Phase 1
-
A Safety and Efficacy Study Evaluating CTX131 in Adult Subjects With Relapsed or Refractory Solid Tumors
COMPLETED · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.